Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

E&C investigation

This article was originally published in The Tan Sheet

Executive Summary

The House Energy and Commerce Subcommittee on Oversight and Investigations announces Aug. 24 it is investigating FDA's plan to outsource jobs. Energy and Commerce Chairman John Dingell, D-Mich., and Subcommittee Chair Bart Stupak, D-Mich., say in a release they were "incredulous" when they learned of FDA's plan to outsource 332 positions. The news comes one week after Dingell and Stupak commended the Office of Regulatory Affairs' plan to shut down seven labs (1"The Tan Sheet" Aug. 27, 2007, p. 6). The congressmen are asking for a list of the positions as well as descriptions of job responsibilities, records reflecting the plans, budget analyses and more by Sept. 7...

You may also be interested in...



ORA Lab Closings Cancelled But Reorganization Not Off The Table – Staffers

FDA's head of regulatory affairs' Aug. 17 message to staff about cancelling plans to close seven field labs did not mark the end of the agency's ORA reorganization work, staff members say

Optibac Launches Natural Children’s Probiotic Immunity Supplement In Sustainable Pack

The UK's Optibac responds to sustainability and naturals trends with an all-in-one immunity and gut health food supplement especially designed for children.

India To Scrap Intellectual Property Appellate Board: Should Pharma Worry?

Legal experts tell the Pink Sheet why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.

Topics

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel